Escherichia coli‐associated granulomatous colitis in dogs treated according to antimicrobial susceptibility profiling

• DOI: 10.1111/jvim.15995
• Publication Date: 2020-12-15T23:04:55Z
• Authors: Alison C. Manchester; Belgin Dogan; Yongli Guo; Kenneth W. Simpson
• Keywords: Veterinary medicine; diarrhea; boxer; canine; Microbial Sensitivity Tests; 04 agricultural and veterinary sciences; fluoroquinolone; Anti-Bacterial Agents; 3. Good health; resistance; 0403 veterinary science; Dogs; Crohn Disease; antibiotic; Drug Resistance, Multiple, Bacterial; SF600-1100; Drug Resistance, Bacterial; Escherichia coli; Animals; SMALL ANIMAL; Dog Diseases; Escherichia coli Infections; Fluoroquinolones

Eradication of intramucosal Escherichia coli correlates with remission periodic acid-Schiff-positive E coli-associated granulomatous colitis (GC). Treatment failures attributed to multidrug resistant (MDR) bacteria necessitate alternative approaches.Determine clinical outcome GC in dogs treated based on antimicrobial susceptibility profiling and characterize phylogeny resistance mechanisms.Twenty Boxers 4 French Bulldogs GC.Culture, profiling, molecular characterization were performed response treatment was evaluated.Initial biopsy sample culture yielded fluoroquinolone-sensitive (FQ-S) from 9/24 fluoroquinolone-resistant (FQ-R) 15/24. All but 1 FQ-R MDR macrophage-penetrating antimicrobials restricted carbapenems 13/15 dogs. Of 22/24 8/9 FQ-S had complete initial (CR) during fluoroquinolone (FQ) treatment, whereas 9/13 or partial (PR) meropenem doxycycline treatment. In 5/9 12/13 follow-up ≥3 months, CR sustained 5/5 (median, 25 months; range, 4-46) 6/12 long-term 59 range 15-102), 4/12 PR 19 5-65), 2/12 no (NR). Four died within years diagnosis, including 2 euthanized for refractory colitis. genetically diverse. Fluoroquinolone associated mutations gyrA parC, plasmid-mediated less common.Antimicrobial guided by positive outcomes >80% cases. Fluoroquinolone-resistance widespread not clonal. Further study is required optimize GC.